United StatesBreaking News

Galmed Pharmaceuticals (NASDAQ:GLMD) closed its Colospan acquisition, gaining a device tested on 97 patients.

Definium Therapeutics (NASDAQ:DFTX) stated its depression drug trial succeeded, showing a key 8.1-point improvement over a placebo.

AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.

HawkEye 360 (NYSE:HAWK) achieved record first-quarter 2026 revenue of $49.8 million due to strong global demand.

Merck (NYSE:MRK) announced positive topline results from its Phase 3 study evaluating tulisokibart for active ulcerative colitis.

Ennis (NYSE:EBF) reported a 1.4% increase in first-quarter revenue to $98.6 million for the period ended May 31, 2026.

Petróleo Brasileiro, also known as Petrobas (NYSE:PBR) approved the final investment decision for a $1.2 billion biorefining project to produce renewable fuels.

Baker Hughes (NASDAQ:BKR) is discussing potential commitments with the European Commission to clear its acquisition of Chart Industries (NYSE:GTLS).

MOGU (NYSE:MOGU) posted an 11.2% decline in fiscal year 2026 total revenues to RMB125.4 million due to heightened competition.

ECARX (NASDAQ:ECX) signed a definitive agreement to acquire the Flyme software business for RMB1.8 billion ($266 million)

Amundi Investment Institute Head Monica Defend discusses the market reaction to Keir Starmer's announcement that he will step down as British prime minister. Speaking on Bloomberg Television, she says "this was largely expected," which justifies the "containment in volatility." Defend adds there is still value on the yield and that "the real story is one of fiscal discipline."

HF Foods Group (NASDAQ:HFFG) expanded its board from four to five members by appointing Taylor S. Brown.